title: COPD: Novel therapeutics and management strategies--SMi's 7th Annual Conference (October 19-20, 2015--London, UK).
abstract: In 2004 the WHO estimated that 64 million people worldwide suffered from chronic obstructive pulmonary disease (COPD), with 3 million dying from related complications in 2005. Although many patients go undiagnosed, the number of people with the disease continues to increase, and by 2030 it is thought it will be the third most common cause of death in the world. With no cure for COPD, treatment of symptoms increased the European health bill by USD 10 million last year and the market is thought to increase to approximately USD 37.7 million by 2030. These staggering numbers were presented by Frank Thielman (Novartis Pharma) as he opened SMi's Seventh Annual COPD Conference in London, U.K. The meeting gathered experts and scientific pioneers in the respiratory area to discuss developments in known and new therapies, devices and diagnosis, including biomarker models to gain greater disease understanding. This report covers highlights from the 2-day meeting.
authors.affiliation: Thomson Reuters, London, UK. jane.watt@thomsonreuters.com.
authors.forename: J
authors.initials: J
authors.lastname: Watt
authors.affiliation: Thomson Reuters, London, UK. sripadma.ganapathi@thomsonreuters.com.
authors.forename: P
authors.initials: P
authors.lastname: Ganapathi
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008131:London; D057285:Precision Medicine; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
keywords: COPD; Ceramide 1-phosphate; Chronic obstructive pulmonary disease; EXACT-PRO; Inhalers; Overlap syndrome; Personalized therapies; p38 MAPK inhibitors